D
Heron Therapeutics, Inc.
HRTX
$2.48
$0.093.77%
D
Sell
1/10/2025Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D- from E+ on 1/10/2025 due to a significant increase in the growth index and volatility index. Operating cash flow increased 173.22% from -$4.6M to $3.37M, earnings per share increased from -$0.0606 to -$0.0317, and EBIT increased 30.83% from -$6.45M to -$4.46M.
Heron Therapeutics, Inc. (HRTX) was upgraded to D- from E+ on 1/10/2025 due to a significant increase in the growth index and volatility index. Operating cash flow increased 173.22% from -$4.6M to $3.37M, earnings per share increased from -$0.0606 to -$0.0317, and EBIT increased 30.83% from -$6.45M to -$4.46M.
E
Sell
10/31/2024Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D- on 10/31/2024 due to a significant decline in the growth index and valuation index. Earnings per share declined from -$0.0209 to -$0.0606, and EBIT declined 34.33% from -$4.8M to -$6.45M.
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D- on 10/31/2024 due to a significant decline in the growth index and valuation index. Earnings per share declined from -$0.0209 to -$0.0606, and EBIT declined 34.33% from -$4.8M to -$6.45M.
D
Sell
1/12/2024Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D- from E+ on 1/12/2024 due to a major increase in the growth index, valuation index and total return index. Operating cash flow increased 66.21% from -$27.17M to -$9.18M, earnings per share increased from -$0.3513 to -$0.1725, and EBIT increased 29.16% from -$29.4M to -$20.83M.
Heron Therapeutics, Inc. (HRTX) was upgraded to D- from E+ on 1/12/2024 due to a major increase in the growth index, valuation index and total return index. Operating cash flow increased 66.21% from -$27.17M to -$9.18M, earnings per share increased from -$0.3513 to -$0.1725, and EBIT increased 29.16% from -$29.4M to -$20.83M.
E
Sell
3/14/2023Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/9/2023Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D from E+ on 02/09/2023.
Heron Therapeutics, Inc. (HRTX) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index and valuation index. Operating cash flow declined 30.64% from -$28.37M to -$37.07M, and total revenue declined 3.88% from $27.63M to $26.56M.
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index and valuation index. Operating cash flow declined 30.64% from -$28.37M to -$37.07M, and total revenue declined 3.88% from $27.63M to $26.56M.
D
Sell
8/10/2022Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D from D- on 8/10/2022 due to a major increase in the growth index and valuation index. Operating cash flow increased 35.43% from -$43.94M to -$28.37M, EBIT increased 21.34% from -$62.92M to -$49.5M, and total revenue increased 17.79% from $23.46M to $27.63M.
Heron Therapeutics, Inc. (HRTX) was upgraded to D from D- on 8/10/2022 due to a major increase in the growth index and valuation index. Operating cash flow increased 35.43% from -$43.94M to -$28.37M, EBIT increased 21.34% from -$62.92M to -$49.5M, and total revenue increased 17.79% from $23.46M to $27.63M.
D
Sell
5/11/2022Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D- from E+ on 5/11/2022 due to an increase in the volatility index.
Heron Therapeutics, Inc. (HRTX) was upgraded to D- from E+ on 5/11/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/26/2022Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D from E+ on 04/26/2022.
Heron Therapeutics, Inc. (HRTX) was upgraded to D from E+ on 04/26/2022.
E
Sell
4/20/2022Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
D
Sell
4/19/2022Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D from D- on 4/19/2022 due to an increase in the volatility index.
Heron Therapeutics, Inc. (HRTX) was upgraded to D from D- on 4/19/2022 due to an increase in the volatility index.
D
Sell
3/30/2022Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to D- from D on 3/30/2022 due to a noticeable decline in the solvency index, growth index and volatility index. Debt to equity increased from 1.28 to 1.95, the quick ratio declined from 3.4 to 2.72, and total revenue declined 11.08% from $23.23M to $20.66M.
Heron Therapeutics, Inc. (HRTX) was downgraded to D- from D on 3/30/2022 due to a noticeable decline in the solvency index, growth index and volatility index. Debt to equity increased from 1.28 to 1.95, the quick ratio declined from 3.4 to 2.72, and total revenue declined 11.08% from $23.23M to $20.66M.
D
Sell
11/9/2021Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D from E+ on 11/09/2021.
Heron Therapeutics, Inc. (HRTX) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index, solvency index and valuation index. Debt to equity increased from 0.95 to 1.28, and the quick ratio declined from 3.66 to 3.4.
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index, solvency index and valuation index. Debt to equity increased from 0.95 to 1.28, and the quick ratio declined from 3.66 to 3.4.
D
Sell
8/18/2021Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to D- from D on 8/18/2021 due to a substantial decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.05 to 0.95.
Heron Therapeutics, Inc. (HRTX) was downgraded to D- from D on 8/18/2021 due to a substantial decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.05 to 0.95.
D
Sell
4/20/2020Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D from D- on 4/20/2020 due to an increase in the volatility index and total return index.
Heron Therapeutics, Inc. (HRTX) was upgraded to D from D- on 4/20/2020 due to an increase in the volatility index and total return index.
D
Sell
4/3/2020Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to D- from D on 4/3/2020 due to a decline in the total return index and volatility index.
Heron Therapeutics, Inc. (HRTX) was downgraded to D- from D on 4/3/2020 due to a decline in the total return index and volatility index.
D
Sell
3/19/2020Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D from D- on 3/19/2020 due to an increase in the valuation index and solvency index. The quick ratio increased from 3.34 to 4.46.
Heron Therapeutics, Inc. (HRTX) was upgraded to D from D- on 3/19/2020 due to an increase in the valuation index and solvency index. The quick ratio increased from 3.34 to 4.46.
D
Sell
5/15/2019Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to D- from D on 5/15/2019 due to a decline in the total return index, efficiency index and growth index. Operating cash flow declined 46.4% from -$33.49M to -$49.02M, EBIT declined 30.67% from -$49.51M to -$64.7M, and net income declined 27.15% from -$49.56M to -$63.01M.
Heron Therapeutics, Inc. (HRTX) was downgraded to D- from D on 5/15/2019 due to a decline in the total return index, efficiency index and growth index. Operating cash flow declined 46.4% from -$33.49M to -$49.02M, EBIT declined 30.67% from -$49.51M to -$64.7M, and net income declined 27.15% from -$49.56M to -$63.01M.
D
Sell
2/25/2019Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to D from D+ on 2/25/2019 due to a large decline in the efficiency index, volatility index and solvency index. The quick ratio declined from 6.53 to 4.31, net income declined 29.24% from -$38.35M to -$49.56M, and total capital declined 8.86% from $411.15M to $374.73M.
Heron Therapeutics, Inc. (HRTX) was downgraded to D from D+ on 2/25/2019 due to a large decline in the efficiency index, volatility index and solvency index. The quick ratio declined from 6.53 to 4.31, net income declined 29.24% from -$38.35M to -$49.56M, and total capital declined 8.86% from $411.15M to $374.73M.
D
Sell
2/15/2019Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D+ from D on 2/15/2019 due to an increase in the volatility index.
Heron Therapeutics, Inc. (HRTX) was upgraded to D+ from D on 2/15/2019 due to an increase in the volatility index.
D
Sell
1/22/2019Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to D from D+ on 1/22/2019 due to a decline in the valuation index and total return index.
Heron Therapeutics, Inc. (HRTX) was downgraded to D from D+ on 1/22/2019 due to a decline in the valuation index and total return index.
D
Sell
1/7/2019Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D+ from D on 1/7/2019 due to an increase in the valuation index and volatility index.
Heron Therapeutics, Inc. (HRTX) was upgraded to D+ from D on 1/7/2019 due to an increase in the valuation index and volatility index.
D
Sell
12/21/2018Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to D from D+ on 12/21/2018 due to a noticeable decline in the total return index, growth index and volatility index. EBIT declined 7.53% from -$38.85M to -$41.78M.
Heron Therapeutics, Inc. (HRTX) was downgraded to D from D+ on 12/21/2018 due to a noticeable decline in the total return index, growth index and volatility index. EBIT declined 7.53% from -$38.85M to -$41.78M.
D
Sell
9/19/2018Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to D+ from C- on 9/19/2018 due to a noticeable decline in the total return index.
Heron Therapeutics, Inc. (HRTX) was downgraded to D+ from C- on 9/19/2018 due to a noticeable decline in the total return index.
C
Hold
8/9/2018Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to C- from D- on 8/9/2018 due to a major increase in the growth index, efficiency index and solvency index. Total capital increased 280.68% from $121.1M to $461M, the quick ratio increased from 1.66 to 5.96, and debt to equity declined from 0.31 to 0.07.
Heron Therapeutics, Inc. (HRTX) was upgraded to C- from D- on 8/9/2018 due to a major increase in the growth index, efficiency index and solvency index. Total capital increased 280.68% from $121.1M to $461M, the quick ratio increased from 1.66 to 5.96, and debt to equity declined from 0.31 to 0.07.
D
Sell
2/28/2018Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to D- from D on 2/28/2018 due to a decline in the growth index, efficiency index and valuation index. EBIT declined 57.34% from -$41.11M to -$64.69M, net income declined 49.26% from -$41.87M to -$62.49M, and earnings per share declined from -$0.7728 to -$1.0845.
Heron Therapeutics, Inc. (HRTX) was downgraded to D- from D on 2/28/2018 due to a decline in the growth index, efficiency index and valuation index. EBIT declined 57.34% from -$41.11M to -$64.69M, net income declined 49.26% from -$41.87M to -$62.49M, and earnings per share declined from -$0.7728 to -$1.0845.
D
Sell
8/10/2017Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D from D- on 8/10/2017 due to a large increase in the growth index, volatility index and solvency index. Total revenue increased 134.31% from $3.63M to $8.51M, operating cash flow increased 36.68% from -$50.58M to -$32.03M, and debt to equity declined from 0.52 to 0.41.
Heron Therapeutics, Inc. (HRTX) was upgraded to D from D- on 8/10/2017 due to a large increase in the growth index, volatility index and solvency index. Total revenue increased 134.31% from $3.63M to $8.51M, operating cash flow increased 36.68% from -$50.58M to -$32.03M, and debt to equity declined from 0.52 to 0.41.
D
Sell
2/24/2017Upgraded
Heron Therapeutics, Inc. (HRTX) was upgraded to D- from E+ on 2/24/2017 due to an increase in the valuation index, solvency index and efficiency index. Debt to equity declined from 2.95 to -2.49, and net income increased 1.13% from -$48.51M to -$47.96M.
Heron Therapeutics, Inc. (HRTX) was upgraded to D- from E+ on 2/24/2017 due to an increase in the valuation index, solvency index and efficiency index. Debt to equity declined from 2.95 to -2.49, and net income increased 1.13% from -$48.51M to -$47.96M.
E
Sell
2/8/2017Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D- on 2/8/2017 due to a large decline in the solvency index, volatility index and total return index. Debt to equity increased from 0.04 to 2.95.
Heron Therapeutics, Inc. (HRTX) was downgraded to E+ from D- on 2/8/2017 due to a large decline in the solvency index, volatility index and total return index. Debt to equity increased from 0.04 to 2.95.
D
Sell
3/11/2016Downgrade
Heron Therapeutics, Inc. (HRTX) was downgraded to D- from D on 3/11/2016 due to a noticeable decline in the volatility index, efficiency index and valuation index. Net income declined 37.8% from -$22.67M to -$31.24M, and total capital declined 16.3% from $143.76M to $120.33M.
Heron Therapeutics, Inc. (HRTX) was downgraded to D- from D on 3/11/2016 due to a noticeable decline in the volatility index, efficiency index and valuation index. Net income declined 37.8% from -$22.67M to -$31.24M, and total capital declined 16.3% from $143.76M to $120.33M.
NASDAQ
03/18/2025 4:00PM Eastern
Quotes delayed
